Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

Liliana Antunes; Clara Mazagatos; Iván Martínez-Baz; Verónica Gomez; Maria-Louise Borg; Goranka Petrović; Róisín Duffy; François E Dufrasne; Ralf Dürrwald; Mihaela Lazar; Ligita Jancoriene; Beatrix Oroszi; Petr Husa; Jennifer Howard; Aryse Melo; Francisco Pozo; Gloria Pérez-Gimeno; Jesús Castilla; Ausenda Machado; Aušra Džiugytė; Svjetlana Karabuva; Margaret Fitzgerald; Sébastien Fierens; Kristin Tolksdorf; Silvia-Odette Popovici; Auksė Mickienė; Gergő Túri; Lenka Součková; Nathalie Nicolay; Angela MC Rose; on behalf of the European Hospital Vaccine Effectiveness Group

doi:10.2807/1560-7917.ES.2024.29.3.2300708

Rapid communication Open Access

Like 0

Download

Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
Liliana Antunes¹ , Clara Mazagatos^2,3 , Iván Martínez-Baz^4,5 , Verónica Gomez⁶ , Maria-Louise Borg⁷ , Goranka Petrović⁸ , Róisín Duffy⁹ , François E Dufrasne¹⁰ , Ralf Dürrwald¹¹ , Mihaela Lazar¹² , Ligita Jancoriene¹³ , Beatrix Oroszi¹⁴ , Petr Husa¹⁵ , Jennifer Howard¹ , Aryse Melo¹⁶ , Francisco Pozo¹⁷ , Gloria Pérez-Gimeno^2,3 , Jesús Castilla^4,5 , Ausenda Machado⁶ , Aušra Džiugytė⁷ , Svjetlana Karabuva¹⁸ , Margaret Fitzgerald⁹ , Sébastien Fierens¹⁹ , Kristin Tolksdorf²⁰ , Silvia-Odette Popovici²¹ , Auksė Mickienė²² , Gergő Túri¹⁴ , Lenka Součková¹⁵ , Nathalie Nicolay²³ , Angela MC Rose¹ , on behalf of the European Hospital Vaccine Effectiveness Group²⁴
View Affiliations Hide Affiliations

Affiliations: ¹ Epiconcept, Paris, France ² National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain ³ Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain ⁴ Instituto de Salud Pública de Navarra – IdiSNA, Pamplona, Spain ⁵ CIBER Epidemiología y Salud Pública, Madrid, Spain ⁶ Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal ⁷ Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta ⁸ Croatian Institute of Public Health, Zagreb, Croatia ⁹ Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland ¹⁰ National Influenza Centre Laboratory of Viral Diseases, Sciensano, Brussels, Belgium ¹¹ National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany ¹² Cantacuzino National Military-Medical Institute for Research and Development, Bucharest, Romania ¹³ Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Lithuania ¹⁴ National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary ¹⁵ University Hospital Brno, Masaryk University, Brno, Czechia ¹⁶ Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal ¹⁷ National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain ¹⁸ University Hospital Centre Split, Split, Croatia ¹⁹ Service Epidemiology of Infectious Diseases, Sciensano, Brussels, Belgium ²⁰ Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany ²¹ National Institute of Public Health, National Centre for Communicable Diseases Surveillance and Control, Bucharest, Romania ²² Department of Infectious Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania ²³ European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden ²⁴ Members of the European Hospital Vaccine Effectiveness Group are listed under Acknowledgements

Correspondence:
Liliana Antunes
l.antunes epiconcept.fr
View Citation Hide Citation

Citation style for this article: Antunes Liliana, Mazagatos Clara, Martínez-Baz Iván, Gomez Verónica, Borg Maria-Louise, Petrović Goranka, Duffy Róisín, Dufrasne François E, Dürrwald Ralf, Lazar Mihaela, Jancoriene Ligita, Oroszi Beatrix, Husa Petr, Howard Jennifer, Melo Aryse, Pozo Francisco, Pérez-Gimeno Gloria, Castilla Jesús, Machado Ausenda, Džiugytė Aušra, Karabuva Svjetlana, Fitzgerald Margaret, Fierens Sébastien, Tolksdorf Kristin, Popovici Silvia-Odette, Mickienė Auksė, Túri Gergő, Součková Lenka, Nicolay Nathalie, Rose Angela MC, on behalf of the European Hospital Vaccine Effectiveness Group. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023. Euro Surveill. 2024;29(3):pii=2300708. https://doi.org/10.2807/1560-7917.ES.2024.29.3.2300708 Received: 15 Dec 2023; Accepted: 18 Jan 2024

Abstract

We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.

This work is licensed under a Creative Commons Attribution 4.0 International License.

Closure

A corrected article has been published for this content:

Authors’ correction for Euro Surveill. 2024;29(3)

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.3.2300708

2024-01-18

2024-04-27

Click here for cited by

http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.3.2300708

Full text loading...

/deliver/fulltext/eurosurveillance/29/3/eurosurv-29-3-2.html?itemId=/content/10.2807/1560-7917.ES.2024.29.3.2300708&mimeType=html&fmt=ahah

References

European Medicines Agency (EMA). Authorised COVID-19 vaccines. Amsterdam: EMA. [Accessed: 2 Nov 2023]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines
European Centre for Disease Prevention and Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Overview-vaccination-strategies-COVID-19-8-September-2022.pdf
European Centre for Disease Prevention and Control (ECDC). ECDC de-escalates BA.2, BA.4 and BA.5 from its list of variants of concern. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/news-events/ecdc-de-escalates-ba2-ba4-and-ba5-its-list-variants-concern
European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza - Version 2.0. Stockholm: ECDC. 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/core-protocol-ecdc-studies-covid-19-vaccine-effectiveness-against-0
Peralta-Santos A. Assessment of COVID-19 surveillance case definitions and data reporting in the European Union. Briefing requested by the ENVI committee. Brussels: European Parliament; 2020. Available from: http://www.europarl.europa.eu/RegData/etudes/BRIE/2020/652725/IPOL_BRI(2020)652725_EN.pdf
European Centre for Disease Prevention and Control (ECDC). Data on SARS-CoV-2 variants in the EU/EEA. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/data-virus-variants-covid-19-eueea
Fabiani M, Mateo-Urdiales A, Sacco C, Rota MC, Fotakis EA, Petrone D, et al. Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023. Euro Surveill. 2023;28(32):2300397. https://doi.org/10.2807/1560-7917.ES.2023.28.32.2300397 PMID: 37561053
Kirsebom FCM, Harman K, Lunt RJ, Andrews N, Groves N, Abdul Aziz N, et al. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England. Lancet Reg Health Eur. 2023;35(Oct):100755. https://doi.org/10.1016/j.lanepe.2023.100755 PMID: 38115965
Lin DY, Xu Y, Gu Y, Zeng D, Sunny SK, Moore Z. Durability of bivalent boosters against Omicron subvariants. N Engl J Med. 2023;388(19):1818-20. https://doi.org/10.1056/NEJMc2302462 PMID: 37043647
Rose AM, Nicolay N, Sandonis Martín V, Mazagatos C, Petrović G, Baruch J, et al. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022. Euro Surveill. 2023;28(47):2300187. https://doi.org/10.2807/1560-7917.ES.2023.28.47.2300187 PMID: 37997665
European Centre for Disease Prevention and Control (ECDC). Interim public health considerations for COVID-19 vaccination roll-out during 2023. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/interim-public-health-considerations-covid-19-vaccination-roll-out-during-2023
Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Lopez Bernal J. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study. Lancet Infect Dis. 2023;23(11):1235-43. https://doi.org/10.1016/S1473-3099(23)00365-1 PMID: 37453440

Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

Citation style for this article: <a href="/search?value1=Liliana+Antunes&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Antunes Liliana</a>, <a href="/search?value1=Clara+Mazagatos&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mazagatos Clara</a>, <a href="/search?value1=Iv%C3%A1n+Mart%C3%ADnez-Baz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez-Baz Iván</a>, <a href="/search?value1=Ver%C3%B3nica+Gomez&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gomez Verónica</a>, <a href="/search?value1=Maria-Louise+Borg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Borg Maria-Louise</a>, <a href="/search?value1=Goranka+Petrovi%C4%87&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Petrović Goranka</a>, <a href="/search?value1=R%C3%B3is%C3%ADn+Duffy&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Duffy Róisín</a>, <a href="/search?value1=Fran%C3%A7ois+E+Dufrasne&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dufrasne François E</a>, <a href="/search?value1=Ralf+D%C3%BCrrwald&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dürrwald Ralf</a>, <a href="/search?value1=Mihaela+Lazar&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lazar Mihaela</a>, <a href="/search?value1=Ligita+Jancoriene&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jancoriene Ligita</a>, <a href="/search?value1=Beatrix+Oroszi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Oroszi Beatrix</a>, <a href="/search?value1=Petr+Husa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Husa Petr</a>, <a href="/search?value1=Jennifer+Howard&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Howard Jennifer</a>, <a href="/search?value1=Aryse+Melo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Melo Aryse</a>, <a href="/search?value1=Francisco+Pozo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pozo Francisco</a>, <a href="/search?value1=Gloria+P%C3%A9rez-Gimeno&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pérez-Gimeno Gloria</a>, <a href="/search?value1=Jes%C3%BAs+Castilla&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Castilla Jesús</a>, <a href="/search?value1=Ausenda+Machado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Machado Ausenda</a>, <a href="/search?value1=Au%C5%A1ra+D%C5%BEiugyt%C4%97&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Džiugytė Aušra</a>, <a href="/search?value1=Svjetlana+Karabuva&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Karabuva Svjetlana</a>, <a href="/search?value1=Margaret+Fitzgerald&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fitzgerald Margaret</a>, <a href="/search?value1=S%C3%A9bastien+Fierens&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fierens Sébastien</a>, <a href="/search?value1=Kristin+Tolksdorf&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Tolksdorf Kristin</a>, <a href="/search?value1=Silvia-Odette+Popovici&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Popovici Silvia-Odette</a>, <a href="/search?value1=Auks%C4%97+Mickien%C4%97&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mickienė Auksė</a>, <a href="/search?value1=Gerg%C5%91+T%C3%BAri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Túri Gergő</a>, <a href="/search?value1=Lenka+Sou%C4%8Dkov%C3%A1&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Součková Lenka</a>, <a href="/search?value1=Nathalie+Nicolay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nicolay Nathalie</a>, <a href="/search?value1=Angela+MC+Rose&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rose Angela MC</a>, <a href="/search?value1=on+behalf+of+the+European+Hospital+Vaccine+Effectiveness+Group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the European Hospital Vaccine Effectiveness Group</a>. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(3):pii=2300708. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.3.2300708" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.3.2300708</a> Received: 15 Dec 2023;   Accepted: 18 Jan 2024

/content/10.2807/1560-7917.ES.2024.29.3.2300708

Data & Media loading...

Supplementary data

Download
- Supplement

Submit comment

Comment moderation successfully completed

Submit your article here

Submit an Article

Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

Abstract

Click here for cited by

Supplementary data

Supplement

Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023